Skip to main content
OpenTrials
Completed

NCT Number: NCT02872038

Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis

The purpose of this study is to compare the efficacy of empirical antibiotics of CAPD-associated peritonitis with intraperitoneal, continuous dosing of cefepime monotherapy versus combination of cefazolin and ceftazidime. Patients were randomized to be administered either intraperitoneal cefepime 1 g loading then 250 mg all exchanges (treatment group) or cefazolin and ceftazidime (control group) in the same dose.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Chulalongkorn University

Bangkok, 10500, Thailand

About this study

The International Society of Peritoneal Dialysis (ISPD) guideline suggest to use combination of antibiotics to cover both of gram positive and gram negative bacteria. The usual regimen in Thailand is cefazolin plus ceftazidime. Despite combination therapy, monotherapy is also possible for empirical treatment of CAPD-associated peritonitis since it helps to lowering staff burden and lowering risk of contamination. Cefepime could be an ideal antibiotic for empirical treatment of CAPD-associated peritonitis as it is an extended-spectrum cephalosporin, forth generation, covering most of gram positive and gram negative bacteria. In addition, cefepime is not broken down by many of the beta-lactamases and less beta-lactamases inducer. This study aims to prove the noninferiority of cefepime monotherapy to cefazolin plus ceftazidime for empirical treatment of CAPD-associated peritonitis.

CAPD-associated peritonitis was diagnosed by at least two of the following criteria: abdominal pain or cloudy peritoneal dialysis fluid (PDF); PDF white cell count > 100/μL with > 50% polymorphonuclear(PMN); and positive gram stain or culture. The patients were randomized into two groups by block of four randomization, sealed envelope. Treatment group was treated with intraperitoneal (IP) cefepime 1 g loading following by maintenance dose 250 mg IP all exchanges. Control group was treated with cefazolin 1 g IP loading and ceftazidime 1 g IP loading following by maintenance dose of cefazolin and ceftazidime 250 mg IP all exchanges. If a patient had residual urine ≥ 100 ml/day, dose of antibiotics would be increased by 25%.

On the first day, the initial blood tests for complete blood count, electrolyte, BUN, creatinine, calcium, phosphate and magnesium were obtained. While peritoneal dialysis fluid were collected using two methods of bacterial culture, both of centrifugation of 50 ml peritoneal dialysis fluid at 3,000 g for 15 minutes and bedside 5-10 ml of peritoneal dialysis fluid inoculated into the blood culture bottles. PDF gram stain and bacterial culture were done. The patients were followed on day 3, 5, 10, 14, 21 and 28 days after the completion of antibiotic course. If clinical improved, the antibiotics would be adjusted according to the culture result and sensitivity after day 5. If clinical not improved the antibiotics would be step up and Tenckhoff catheter removal was considered (on any day of treatment). The patients were treated at least 14 days or 21 days depend on the culture result (as the recommendation of ISPD guideline 2010).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age more than 18 years
  • CAPD initiation more than 4 weeks

Exclusion criteria

  • Exit site or tunnel infection
  • Sepsis
  • Previous CAPD-associated peritonitis treatment within 4 weeks
  • Drug allergy to cephalosporin
  • Tenckhoff catheter malfunction
  • Hospitalization more than 48 hours
  • Fungal or Mycobacterium infection
  • Suspected secondary peritonitis
  • Concomitant antibiotics.

Treatment and study plan

Cefepime

Drug

Cefepime intraperitoneal continuous dosing

Cefazolin plus Ceftazidime

Drug

Other names: Control group

Primary outcomes

  1. Primary response rate

    Time frame: day 10 of treatment

    Resolution of clinical peritonitis and peritoneal dialysis fluid WBC < 100 /μL with PMN < 50% at day 10

Secondary outcomes

  1. Initial response rate

    Time frame: day 5 of treatment

    Resolution of clinical peritonitis and peritoneal dialysis fluid WBC < 100 /μL with PMN < 50% at day 5

Other outcomes

  1. Complete cure rate

    Time frame: 28 days after completion of antibiotics

    Complete resolution without relapse or recurrent within 28 days after completion of antibiotics.

  2. Relapse peritonitis rate

    Time frame: 28 days after completion antibiotics

    Recur of peritonitis with the same organism or sterile culture within 28 days after completion antibiotics

  3. Recurrent peritonitis rate

    Time frame: 28 days after completion antibiotics

    Recur of peritonitis with different organism within 28 days after completion antibiotics

  4. Death rate

    Time frame: 28 days after completion antibiotics

    Death from any cause

Sponsors and collaborators

Lead sponsor

Chulalongkorn University

Other

Collaborators

  • Siam Pharmaceutical Co Ltd
  • The Kidney Foundation of Thailand

Registry information

Official study title

A Multicenter, Randomized, Controlled Trial Comparing Cefepime Monotherapy Versus Combination of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-associated Peritonitis

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Aug 18, 2016
Registry last updated
Oct 31, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.